Pfizer reported earnings today, including good news for Sandoz and partner Momenta. Pfizer says the FDA this month upgraded the compliance status on a fill-finish plant in Kansas, lifting the hold that has kept Sandoz and Momenta from getting FDA approval for their long-acting Copaxone generic.Original Article
FDA’s upgrade of Pfizer plant bodes well for Sandoz and Momenta’s Copaxone copy
